Oruka Therapeutics, Inc. (ORKA) Stock Forecast & Price Target
Oruka Therapeutics, Inc. · NASDAQ
$90.39+0.20 (+0.22%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Oruka Therapeutics, Inc, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $100.00 to $160.00, a moderate spread. The average target of $132.75 sits 47% above the current $90.39. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.51 next quarter toward $-2.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Strong Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Oruka Therapeutics, Inc.
As of Jul, 11 of 11 firms rate ORKA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ORKA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.73 – $-0.38 · 9 analysts · -8% YoY
Next period, 9 analysts expect Oruka Therapeutics, Inc. to earn $-0.51 a share (range $-0.73 – $-0.38), versus $-0.55 a year earlier. Full-year consensus is $-2.04, growing to $-2.49 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oruka Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORKA.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$200.00+121.3% to target
Overall win rate
52%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$165.00+82.5% to target
Overall win rate
41%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$180.00+99.1% to target
Overall win rate
34%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$120.00+32.8% to target
Overall win rate
34%
+ Follow
#5
Julian Harrison
BTIG
Buy
$151.00+67.0% to target
Coverage
—
+ Follow
ORKA stock forecast FAQ
What is ORKA's average 12-month price target?+
The 4 analysts with a live target average $132.75 for Oruka Therapeutics, Inc. over the next 12 months, ranging from a $160.00 high to a $100.00 low.
Is ORKA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ORKA?+
The Street-high target is $160.00 (Barclays), and the Street-low is $100.00 (UBS). The average of all 4 active targets is $132.75.
How many Wall Street analysts cover ORKA?+
11 analysts have an active rating on Oruka Therapeutics, Inc., and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ORKA?+
Among analysts who currently cover ORKA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $200.00 target.
What is Oruka Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.73 – $-0.38) across 9 analysts. Full-year EPS is projected at $-2.04, rising to $-2.49 the following year.
How much revenue is Oruka Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ORKA lately?+
As of Jul, 11 of 11 firms rate ORKA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORKA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
